Eton Pharmaceuticals (NASDAQ:ETON) announced that the U.S. Patent and Trademark Office (USPTO) has granted the company a patent for its proprietary liquid hydrocortisone, ET-400.
The patent, which expires in 2043, covers a method of using hydrocortisone oral liquid formulations. Eton received its first patent for ET-400 in February 2024 and currently has an additional U.S. patent application under review related to the product.
“We are pleased to have been granted a second patent for ET-400, further strengthening the IP protection of this important asset. Through our interactions with the patient community, we’ve seen firsthand the extensive need and desire for an FDA-approved liquid formulation of hydrocortisone,” said Sean Brynjelsen, CEO of Eton.”
